Patents by Inventor Jan Tebbe

Jan Tebbe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130230886
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 5, 2013
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
  • Patent number: 8481030
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: July 9, 2013
    Assignee: Bayer Healthcare LLC
    Inventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
  • Patent number: 8399627
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: March 19, 2013
    Assignee: Bayer Pharma AG
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
  • Publication number: 20120329996
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Application
    Filed: March 1, 2011
    Publication date: December 27, 2012
    Inventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
  • Publication number: 20120321619
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: December 8, 2010
    Publication date: December 20, 2012
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Lars Linden, Yong-Jiang Cao, Gabriele Leder, Beatrix Stelte-ludwig, Axel Harrenga, Ricarda Finnern, Frank Dittmer, Anke Mayer-Bartschmid, Juergen Franz, Simone Greven, Jörg Willuda, Jan Tebbe
  • Publication number: 20120237496
    Abstract: The present invention relates to polypeptides comprising protease variants of wild type human neprilysin having an altered specificity and/or activity. In particular the present invention relates to polypeptides comprising protease variants derived from human neprilysin having an increased specificity and/or activity against certain substrates, in particular against amyloid beta.
    Type: Application
    Filed: June 21, 2010
    Publication date: September 20, 2012
    Inventors: Joerg Birkenfeld, Andrea Eicker, Per-Ola Freskgard, Claudia Gotzberger-Schad, Joanna Grudzinska, Ulrich Haupts, Josi Innig, Christoph Mahlert, Andreas Scheidig, Michael Strerath, Jan Tebbe, Johan Per-Wallin, Nina Wobst, Carl Innes Webster, Lutz Jermutus
  • Publication number: 20120108796
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Application
    Filed: December 12, 2011
    Publication date: May 3, 2012
    Inventors: Zhuozhi WANG, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
  • Publication number: 20100297700
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Application
    Filed: December 24, 2008
    Publication date: November 25, 2010
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
  • Publication number: 20080160558
    Abstract: A process for generating sequence-specific proteases by screening-based directed evolution is disclosed. The use of the process provides proteases recognizing and cleaving user-definable amino-acid sequences with high sequence-specificity. Proteases obtainable by the process can be used in a variety of medical, diagnostic and industrial applications.
    Type: Application
    Filed: May 9, 2007
    Publication date: July 3, 2008
    Applicant: DIREVO BIOTECH AG
    Inventors: ANDRE KOLTERMANN, ULRICH KETTLING, ULRICH HAUPTS, JAN TEBBE, PETER SCHOLZ, JENS PILLING, SUSANNE WERNER, MARKUS RARBACH
  • Publication number: 20060269538
    Abstract: The present invention provides variants of serine proteases of the S1 class with altered sensitivity to one or more activity-modulating substances. A method for the generation of such proteases is disclosed, comprising the provision of a protease library encoding polynucleotide sequences, expression of the enzymes, screening of the library in the presence of one or several activity-modulating substances, selection of variants with altered sensitivity to one or several activity-modulating substances and isolation of those polynucleotide sequences that encode for the selected variants.
    Type: Application
    Filed: May 26, 2006
    Publication date: November 30, 2006
    Inventors: Andre Koltermann, Ulrich Kettling, Ulrich Haupts, Wayne Coco, Jan Tebbe, Christian Votsmeier, Andreas Scheidig
  • Publication number: 20040072276
    Abstract: A process for generating sequence-specific proteases by screening-based directed evolution is disclosed. The use of the process provides proteases recognizing and cleaving user-definable amino-acid sequences with high sequence-specificity. Proteases obtainable by the process can be used in a variety of medical, diagnostic and industrial applications.
    Type: Application
    Filed: May 9, 2003
    Publication date: April 15, 2004
    Applicant: Direvo BioTech AG.
    Inventors: Andre Koltermann, Ulrich Kettling, Ulrich Haupts, Jan Tebbe, Peter Scholz, Jens Pilling, Susanne Werner, Markus Rarbach